<DOC>
	<DOCNO>NCT00920426</DOCNO>
	<brief_summary>The purpose randomize , double-blinded study test safety GSK1265744 well work reduce amount HIV blood . It also look people react human body use GSK1265744 . This study compare effect GSK1265744 placebo . The study consist 1 2 part look dose GSK1265744 . About 8 people take part Part 1 study receive dose A . If additional dosing information need Part 1 , 6 people take part Part 2 study receive dose B .</brief_summary>
	<brief_title>Study Compare Safety Anti-HIV Effect GSK1265744 Versus Placebo HIV-1 Infected Adults ( ITZ112929 )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential , define : Premenopausal female document bilateral oophorectomy , tubal ligation hysterectomy ; Postmenopausal define 12 month spontaneous amenorrhea . A follicle stimulate hormone level perform confirm postmenopausal status . For study , FSH level &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 14 day last dose study medication . CD4+ cell count great equal 200 cells/mm3 plasma HIV1 RNA great equal 5000 copies/mL Screening . No current antiretroviral therapy receive 12 week prior first dose . For subject receive antiretroviral treatment past , adequate treatment option construct HAART therapy least 3 active antiretrovirals Optimized Therapy , select Investigator . Capable give write informed consent , include compliance requirement restriction list consent form . Exclusion Criteria A subject eligible inclusion study follow criterion apply : A positive screening Hepatitis B surface antigen ; positive screening hepatitis C virus ( HCV ) antibody detectable HCV ribonucleic acid ( RNA ) subsequent test . If hepatitis C antibody positive HCV RNA undetectable , subject may include study . AST ALT &gt; 3ULN Screening . A single repeat allow eligibility determination . Inadequate renal function Screening , define either serum creatinine &gt; 1.5 mg/dL calculate creatinine clearance ( CrCl ) ≤ 50 mL/min . A single repeat serum creatinine allow determine eligibility . Any acute laboratory abnormality screening , opinion investigator , preclude subject 's participation study investigational compound . Any grade 4 laboratory abnormality screening , exception CPK , exclude subject study participation unless investigator provide compel explanation laboratory result ( ) assent sponsor . A single repeat allow eligibility determination . A positive drug screen screen baseline . A minimum list drug screen include amphetamine , barbiturate , cocaine PCP . History regular alcohol consumption , define average weekly intake &gt; 14 drink male &gt; 7 drink female , within 6 month Screening . Note : One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . Any condition ( include alcohol drug abuse ) , opinion investigator , could interfere subject 's ability comply dose schedule protocol evaluation might compromise safety subject . Prior treatment integrase inhibitor ( great equal 1 dose ) . Treatment radiation therapy cytotoxic chemotherapeutic agent within 30 day study drug administration anticipate need treatment within study . Treatment immunomodulating agent ( systemic corticosteroid , interleukin , interferon ) agent know antiHIV activity ( hydroxyurea foscarnet ) within 30 day study drug administration . Treatment vaccine within 30 day prior receive study medication . An active Center Disease Control Prevention ( CDC ) Category C disease , except cutaneous Kaposi 's sarcoma require systemic therapy trial . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Use multivitamins antacid within 24 hour prior first dose investigational product . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Note : Study medication refer GSK1265744 placebo . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Where participation study would result donation blood blood product excess 500 mL within 56 day period . History clinically relevant pancreatitis hepatitis within previous 6 month . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Exclusion Criteria Screening ECG ( A single repeat allow eligibility determination ) : Exclusion Criteria Screening ECG : Males Females Heart rate &lt; 45 &gt; 100 bpm &lt; 50 &gt; 100 bpm QRS duration &gt; 120 msec &gt; 120 msec QTc interval ( Bazett ) &gt; 450 msec &gt; 450 msec Nonsustained ( ≥ 3 consecutive beat ) sustain ventricular tachycardia . Sinus Pauses &gt; 3 second . 2nd degree ( Type II ) high AV block . Evidence previous myocardial infarction ( pathologic Q wave , ST segment change ( except early repolarization ) ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>naive</keyword>
	<keyword>Phase II</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>GSK1265744</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>AIDS</keyword>
	<keyword>integrase</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>Treatment naive</keyword>
</DOC>